AR026248A1 - Utilizacion de una bacteria acida lactica para la preparacion de un portador ingerible para el tratamiento y/o profilaxis de la giardiasis - Google Patents

Utilizacion de una bacteria acida lactica para la preparacion de un portador ingerible para el tratamiento y/o profilaxis de la giardiasis

Info

Publication number
AR026248A1
AR026248A1 ARP000105634A ARP000105634A AR026248A1 AR 026248 A1 AR026248 A1 AR 026248A1 AR P000105634 A ARP000105634 A AR P000105634A AR P000105634 A ARP000105634 A AR P000105634A AR 026248 A1 AR026248 A1 AR 026248A1
Authority
AR
Argentina
Prior art keywords
carrier
preparation
treatment
lactic acid
ingerible
Prior art date
Application number
ARP000105634A
Other languages
English (en)
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of AR026248A1 publication Critical patent/AR026248A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1236—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using Leuconostoc, Pediococcus or Streptococcus sp. other than Streptococcus Thermophilus; Artificial sour buttermilk in general
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Dairy Products (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente se refiere al uso de un flotante de la bacteria ácida láctica o Bifidobacteria, capaz de evitar la colonizacion de las células intestinales porla Giardia intestinalis, para la preparacion de un portador que se puede ingerir, para el uso e n el tratamiento y/o profilaxis de los trastornos asociados conla colonizacion del tracto intestinal por la Giardia intestinalis. La presente asimismo está relacionada con las cepas específicas de la Bifidobacteria quetiene las anteriormente menciona das características y al portador ingerible, tal como un alimento o una composicion farmacéutica, que contiene dicho flotante olos microorganismos.
ARP000105634A 1999-10-26 2000-10-26 Utilizacion de una bacteria acida lactica para la preparacion de un portador ingerible para el tratamiento y/o profilaxis de la giardiasis AR026248A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99121356 1999-10-26

Publications (1)

Publication Number Publication Date
AR026248A1 true AR026248A1 (es) 2003-02-05

Family

ID=8239282

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105634A AR026248A1 (es) 1999-10-26 2000-10-26 Utilizacion de una bacteria acida lactica para la preparacion de un portador ingerible para el tratamiento y/o profilaxis de la giardiasis

Country Status (19)

Country Link
US (2) US6905679B1 (es)
EP (1) EP1227827B1 (es)
CN (1) CN1281220C (es)
AP (1) AP1563A (es)
AR (1) AR026248A1 (es)
AT (1) ATE290393T1 (es)
AU (1) AU1025001A (es)
BR (1) BR0015102B1 (es)
CA (1) CA2388952C (es)
CO (1) CO5280049A1 (es)
DE (1) DE60018591T2 (es)
DK (1) DK1227827T3 (es)
ES (1) ES2239622T3 (es)
MX (1) MXPA02004115A (es)
OA (1) OA12074A (es)
PE (1) PE20010676A1 (es)
PT (1) PT1227827E (es)
WO (1) WO2001030365A1 (es)
ZA (1) ZA200203008B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12074A (en) 1999-10-26 2006-05-04 Nestle Sa Lactic acid bacteria for the treatment and/or prophylaxis of giardiasis.
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
EP2124966B1 (en) 2007-02-01 2015-09-09 IAMS Europe B.V. Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
ES2559008T3 (es) * 2009-05-11 2016-02-10 Nestec S.A. Bifidobacterium longum NCC2705 no replicante y trastornos inmunitarios
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EP3011966A1 (en) 2014-08-08 2016-04-27 Institut National De La Recherche Agronomique Compositions for the inhibition of Giardia Lamblia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0577904B1 (fr) * 1992-07-06 1997-05-14 Societe Des Produits Nestle S.A. Bactérie lactique
SE9501056D0 (sv) 1995-03-23 1995-03-23 Probi Ab Epithelial adherent lactobacilli
US5902578A (en) * 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
ATE272320T1 (de) * 1999-04-30 2004-08-15 Nestle Sa Erhöhtes wachstum von milchsäurebakterien im milch
OA12074A (en) 1999-10-26 2006-05-04 Nestle Sa Lactic acid bacteria for the treatment and/or prophylaxis of giardiasis.

Also Published As

Publication number Publication date
US6905679B1 (en) 2005-06-14
DE60018591T2 (de) 2006-04-13
US20050186191A1 (en) 2005-08-25
EP1227827A1 (en) 2002-08-07
AU1025001A (en) 2001-05-08
CA2388952A1 (en) 2001-05-03
PT1227827E (pt) 2005-07-29
ATE290393T1 (de) 2005-03-15
CA2388952C (en) 2008-06-10
EP1227827B1 (en) 2005-03-09
DE60018591D1 (de) 2005-04-14
CN1281220C (zh) 2006-10-25
CN1382056A (zh) 2002-11-27
ZA200203008B (en) 2003-09-23
BR0015102B1 (pt) 2014-03-18
MXPA02004115A (es) 2002-10-17
WO2001030365A1 (en) 2001-05-03
PE20010676A1 (es) 2001-07-11
AP1563A (en) 2006-02-02
AP2002002483A0 (en) 2002-06-30
DK1227827T3 (da) 2005-07-11
ES2239622T3 (es) 2005-10-01
BR0015102A (pt) 2002-07-16
CO5280049A1 (es) 2003-05-30
US7229616B2 (en) 2007-06-12
OA12074A (en) 2006-05-04

Similar Documents

Publication Publication Date Title
AR026248A1 (es) Utilizacion de una bacteria acida lactica para la preparacion de un portador ingerible para el tratamiento y/o profilaxis de la giardiasis
ES2324532T3 (es) Bacteria probiotica: lactobacillus fermentum.
ES2245411T3 (es) Composicion que comprende una cepa de lactobacillus pentosus y usos de la misma.
ES2647833T3 (es) Nueva cepa de Lactobacillus crispatus
AR072435A1 (es) Composicion nutricional para lactantes nacidos por cesarea
PE20061107A1 (es) Composiciones de tigeciclina y metodos para su preparacion
JP2008106066A (ja) サポニン及び生菌を含有する組成物
AR022913A1 (es) Una bacteria de acido lactico que pertenece al genero lactobacillus, el uso de la misma para preparar alimentos y los alimentos y composicionesfarmaceuticas que la contienen
US11446343B2 (en) Probiotic composition for prevention of bacterial vaginosis
ATE521358T1 (de) Vorbeugender und/oder therapeutischer wirkstoff zur behandlung einer funktionellen gastrointestinalen erkrankung
Bali et al. Pharyngeal and peritonsillar abscess due to Leclercia adecarboxylata in an immunocompetant patient
GB2456475A (en) Composition for the treatment of skin conditions
Bonnemaison et al. Comparison of fecal flora following administration of two antibiotic protocols for suspected maternofetal infection
ITRM20120379A1 (it) Terreno di trasporto per l'isolamento e l'identificazione di helicobacter pylori.
WO2011126342A3 (ko) 대잎둥굴레 또는 층층갈고리둥굴레 추출물의 신규한 용도
Chang et al. Chromobacterium violaceum infection in Taiwan: a case report and literature review
KR101730542B1 (ko) 초고압 효소 반응으로 추출된 구취 개선 및 구강 질환 예방용 매실 추출물 및 이의 제조방법
WO2007071986A8 (en) Use of whole bacterial cells (actinomycetales) for maternal administration to modulate offspring immune response
JP7210193B2 (ja) 腸内環境改善剤およびβ－グルクロニダーゼ活性阻害剤
JPWO2011102529A1 (ja) 上皮細胞間接着増強剤およびこれを用いたアレルギー改善、治療または予防剤
Rahimifard et al. Helicobacter pylori and the herbal compound effect
Porter et al. Spectinomycin: minimum inhibitory concentrations for Neisseria gonorrhoeae.
KR102519415B1 (ko) 질염 예방 또는 치료용 조성물
Afşar et al. In-vitro susceptibility of clinical isolates of Escherichia coli to fosfomycin trometamol and other antibiotics
Abramson et al. Synergism of antibiotic combinations against treponemes.

Legal Events

Date Code Title Description
FB Suspension of granting procedure